Axsome Therapeutics’ (AXSM) “Outperform” Rating Reiterated at William Blair

William Blair restated their outperform rating on shares of Axsome Therapeutics (NASDAQ:AXSM) in a research note released on Tuesday morning,RTT News reports.

AXSM has been the topic of a number of other research reports. Bank of America upped their price objective on Axsome Therapeutics from $143.00 to $167.00 and gave the stock a “buy” rating in a research report on Tuesday, February 11th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $121.00 price target on shares of Axsome Therapeutics in a report on Thursday, December 12th. Wells Fargo & Company raised their target price on Axsome Therapeutics from $140.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 12th. StockNews.com upgraded shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, Robert W. Baird upped their target price on shares of Axsome Therapeutics from $112.00 to $116.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat, Axsome Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $155.47.

Axsome Therapeutics Trading Up 1.7 %

Shares of AXSM stock opened at $129.15 on Tuesday. Axsome Therapeutics has a 1-year low of $64.11 and a 1-year high of $134.18. The firm has a market cap of $6.26 billion, a PE ratio of -21.56 and a beta of 1.05. The company has a 50-day moving average of $100.34 and a two-hundred day moving average of $94.46. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.44 and a quick ratio of 2.37.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.01. The firm had revenue of $118.77 million during the quarter, compared to analysts’ expectations of $117.83 million. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 195.76%. On average, analysts predict that Axsome Therapeutics will post -2.26 EPS for the current year.

Insider Transactions at Axsome Therapeutics

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $131.07, for a total transaction of $393,210.00. Following the completion of the sale, the chief financial officer now directly owns 42,187 shares of the company’s stock, valued at approximately $5,529,450.09. This trade represents a 6.64 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 22.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of AXSM. GF Fund Management CO. LTD. purchased a new position in Axsome Therapeutics in the 4th quarter valued at $86,000. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. purchased a new stake in shares of Axsome Therapeutics in the fourth quarter valued at about $2,853,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Axsome Therapeutics by 20.8% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,642 shares of the company’s stock valued at $4,877,000 after acquiring an additional 9,928 shares in the last quarter. Woodline Partners LP raised its holdings in Axsome Therapeutics by 36.8% during the fourth quarter. Woodline Partners LP now owns 408,441 shares of the company’s stock worth $34,558,000 after purchasing an additional 109,872 shares in the last quarter. Finally, Two Sigma Advisers LP lifted its position in Axsome Therapeutics by 85.3% in the fourth quarter. Two Sigma Advisers LP now owns 6,300 shares of the company’s stock valued at $533,000 after purchasing an additional 2,900 shares during the period. Institutional investors and hedge funds own 81.49% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.